Survival of patients with lymphoplasmacytic lymphoma and solitary plasmacytoma in Germany and the United States of America in the early 21
            <sup>st</sup>
            century

Weberpals, Janick; Pulte, Dianne; Jansen, Lina; Luttmann, Sabine; Holleczek, Bernd; Nennecke, Alice; Ressing, Meike; Katalinic, Alexander; Merz, Maximilian; Brenner, Hermann

doi:10.3324/haematol.2016.157768

Cited by 9 publications

(5 citation statements)

References 39 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Plasmacytomas include extramedullary plasmacytoma (EMP), solitary plasmacytoma of bone (SBP), and multiple myeloma (MM) [ 1 ]. SBP is a rare disease with a high recurrence rate, a cumulative incidence of 0.15/100,000, and a poor prognosis for patients with SPB over 60 years of age [ 2 , 3 ]. The diagnosis of SPB is currently based mainly on histological examination and confirmed by tissue biopsy and radiology [ 4 , 5 ].…”

Section: Introductionmentioning

confidence: 99%

Prediction of Solitary Plasmacytoma of Bone in Elderly Patients: A Nomogram and a Risk Classification System for Overall Survival

Zhang

Yang

Tian

et al. 2022

BioMed Research International

View full text Add to dashboard Cite

Background. Solitary plasmacytoma of bone (SPB) is an isolated plasmacytoma of bone origin, most commonly seen in the elderly, with a poor prognosis. So far, there is no precise nomogram to predict the overall survival (OS) of elderly patients with SPB. Our goal is to construct and validate a nomogram for elderly patients with SPB. Methods. This study collected all elderly patients with SPB in the Surveillance, Epidemiology and End Results (SEER) database from 2000 to 2018, and the variables included were age, sex, race, marital status, primary site, grade, stage, surgery, chemotherapy, and radiotherapy. Independent prognostic factors were identified using univariate and multivariate Cox analysis. The nomogram was constructed to predict 1-, 2-, and 3-year OS of elderly patients with SPB. The receiver-operating characteristic (ROC) and the calibration curves were used to differentiate and calibrate the nomogram. The clinical validity of the nomogram was evaluated by decision curve analysis (DCA). The total OS scores of all elderly SPB patients were calculated and divided into two risk subgroups for comparison. Results. A total of 1837 patients diagnosed with SPB were screened from the SEER database, with a final inclusion of 1180 patients ( age ≥ 60 years). Age, radiotherapy, and marital status were significantly correlated with OS. These characteristics were further incorporated into the creation of the nomogram for predicting 1-, 2-, and 3-year OS of elderly patients with SPB. For this predictive model, the area under the ROC curves, calibration curves, and DCA have good performance in terms of differentiation, consistency, and validity, respectively. In addition, patients in the high-risk group (≥96) had a worse prognosis than those in the low-risk group (<96). Conclusion. We constructed a nomogram and a risk classification system that could provide an intuitive and effective tool for clinicians to better predict the OS of elderly SPB patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Prediction of Solitary Plasmacytoma of Bone in Elderly Patients: A Nomogram and a Risk Classification System for Overall Survival

Zhang

Yang

Tian

et al. 2022

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…3 Plasma cell leukemia (PCL) and extramedullary solitary plasmacytomas are biologically and prognostically distinct conditions and therefore not referred to as EMD. 2,4 The reported incidence of EMD has increased, possibly in part due to improved survival in MM patients through the use of enhanced treatment modalities, in particular stem cell transplantation (SCT), proteasome inhibitors (PI), and immunomodulatory drugs (IMiD). 2 According to one study, there has been an increase in EMD detected at the time of MM diagnosis from 4% to 12% between 1971-93 and 2000-2007 patient cohorts, suggesting improved detection by modern imaging techniques.…”

Section: Introductionmentioning

confidence: 99%

Multiple myeloma with central nervous system relapse

et al. 2020

View full text Add to dashboard Cite

C entral nervous system involvement in multiple myeloma is a rare complication but carries a very poor prognosis. We provide a review of current literature, including presentation, treatment and survival data, and describe our experience in a regional hematologic malignancy diagnosis center where, over a 15-year period, ten cases were identified. Although the median age of onset, frequently between 50-60 years, is comparatively young, those diagnosed usually have a preceding diagnosis of multiple myeloma and often have had several lines of treatment. We discuss putative underlying factors such as prior treatment and associations including possible risk factors and features suggestive of a distinct biology. Central nervous system involvement may be challenging to diagnose in myeloma, displaying heterogeneous symptoms that can be confounded by neurological symptoms caused by the typical features of myeloma or treatment side-effects. We discuss the clinical features, imaging and laboratory methods used in diagnosis, and highlight the importance of considering this rare complication when neurological symptoms occur at presentation or, more commonly, during the disease pathway. In the absence of clinical trial data to inform an evidence-based approach to treatment, we discuss current and novel treatment options. Finally, we propose the establishment of an International Registry of such cases as the best way to collect and subsequently disseminate presentation, diagnostic and treatment outcome data on this rare complication of multiple myeloma.

show abstract

“…1, 2 In terms of disease outcomes, the existing studies demonstrate a variable five-year overall survival (OS) rate of 40 to 85%. 2–7 The national guidelines recommend treatment of solitary plasmacytomas with radiation therapy (RT) with or without surgery. 8 However, the optimal radiation dose has been a subject of debate.…”

Section: Introductionmentioning

confidence: 99%

Treatment approaches and outcomes in plasmacytomas: analysis using a national dataset

et al. 2018

View full text Add to dashboard Cite

Solitary plasmacytomas are uncommon plasma cell disorders, which may present as a single bone lesion (P-bone) or extramedullary plasmacytoma (P-EM). There is a paucity of large studies analyzing prognostic factors and outcomes of plasmacytomas. While the treatment of choice is radiation therapy (RT), there is a lack of data evaluating optimal RT dose. In this study, we sought to answer these questions by utilizing the National Cancer Database plasmacytoma data from 2000 to 2011. A total of 5056 patients were included in the study (median age 62 years; range 52-72). To obtain a pure plasmacytoma cohort, potential multiple myeloma patients were excluded from the study (bone marrow involvement, systemic chemotherapy use). P-bone constituted 70% of the patients. The median overall survival (OS) of P-EM was significantly longer than P-bone (132 vs. 85 months), and for soft/connective tissue it was worse than remainder of P-EM (82 vs. 148 months). On multivariable analysis, factors associated with worse OS included older age (≥65), presence of P-bone, and treatment with a radiation dose <40 Gy.

show abstract

Survival of patients with lymphoplasmacytic lymphoma and solitary plasmacytoma in Germany and the United States of America in the early 21 ^st century

Cited by 9 publications

References 39 publications

Prediction of Solitary Plasmacytoma of Bone in Elderly Patients: A Nomogram and a Risk Classification System for Overall Survival

Prediction of Solitary Plasmacytoma of Bone in Elderly Patients: A Nomogram and a Risk Classification System for Overall Survival

Multiple myeloma with central nervous system relapse

Treatment approaches and outcomes in plasmacytomas: analysis using a national dataset

Contact Info

Product

Resources

About

Survival of patients with lymphoplasmacytic lymphoma and solitary plasmacytoma in Germany and the United States of America in the early 21 st century

Cited by 9 publications

References 39 publications

Prediction of Solitary Plasmacytoma of Bone in Elderly Patients: A Nomogram and a Risk Classification System for Overall Survival

Prediction of Solitary Plasmacytoma of Bone in Elderly Patients: A Nomogram and a Risk Classification System for Overall Survival

Multiple myeloma with central nervous system relapse

Treatment approaches and outcomes in plasmacytomas: analysis using a national dataset

Contact Info

Product

Resources

About

Survival of patients with lymphoplasmacytic lymphoma and solitary plasmacytoma in Germany and the United States of America in the early 21 ^st century